*Yoshihara, K., Baba, T.,*Tokunaga, H.,*Nishino, K.,*Sekine, M.,* Takamatsu, S.,*Matsumura, N.,*Yoshida,H.,* Kajiyama, H.,*Shimada, M.,*Kagimura, T.,*Oda, K., *Sasajima, Y.,*Yaegashi, N.,*Okamoto, A.,* Sugiyama, T.,*Enomoto, T.: Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: JGOG3025 study. Cancer Sci.: 114(6): 2515-2523(2023)
*Yoshihara, K., Baba, T.,*Tokunaga, H.,*Nishino, K.,*Sekine, M.,* Takamatsu, S.,*Matsumura, N.,*Yoshida,H.,* Kajiyama, H.,*Shimada, M.,*Kagimura, T.,*Oda, K., *Sasajima, Y.,*Yaegashi, N.,*Okamoto, A.,* Sugiyama, T.,*Enomoto, T.: Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: JGOG3025 study. Cancer Sci.: 114(6): 2515-2523(2023)
*Akashi, H.,*Yachida, N.,*Ueda, H.,*Yamaguchi, M.,*Yamawaki, K.,*Tamura, R.,*Suda, K.,*Ishiguro, T.,*Adachi, S.,*Nagase, Y.,*Ueda, Y.,*Ueda, M.,*Abiko, K., Kagabu, M., Baba, T.,*Nakaoka, H., *Enomoto, T.,*Murai, J.,*Yoshihara, K.: SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma. Mol Cancer Ther. 23(1): 106-116(2024)
*Miyamoto, S.,*Hirakawa, T.,*Noguchi, Y., *Urushiyama, D.,*Miyata, K., Baba, T.,*Yotsumoto, F.,*Yasunaga, S.,*Nakabayashi, K.,*Hata, K., *Nakagawa, W.,*Otsuka, T.,*Nozawa, Y.,*Furuhata, I.,*Mikasa, J.: Physical Properties of Ultrafine Bubbles Generated Using a Generator System. In Vivo.: Nov-Dec;37(6): 2555-2563(2023)
Nagasawa, T., Shoji, T., Takatori, E., Kaido, Y., Kagabu, M.,*Shimizu, D.,*Shigeto ,T., Baba, T.,* Sugiyama, T.,*Yokoyama, Y.: A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study). Cancers (Basel).: 15(21): 5201(2023)
*Seino, M.,*Nagase, S.,*Tokunaga, H.,*Yamagami, W.,*Kobayashi, Y.,*Tabata, T.,*Kaneuchi, M., *Hirashima, Y.,*Niikura, H.,*Yoshino, K.,*Takehara, K., Baba, T.,*Katabuchi, H.,*Mikami, M.: Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment. J Gynecol Oncol.: 35(1): e15(2024)
*Abe, M., Shoji, T., Chiba, Y., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M.,*Takahashi, F.,*Aida, T., Baba, T.: Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer Res. 43(3): 1265-1272(2023)
Jonai, N., Shoji, T.,*Kanasugi, T.,*Yodogawa, Y., *Takeshita, R.,*Ito, R.,*Abe, M.: Efficacy of Granisetron in the Treatment of Nausea and Vomiting Post-Cesarean Section (A Single Centre Retrospective Cohort Study). Gynecol Obstet Open Acc.: 7: 154(2023)
Chiba, Y., Kagabu, M., Osakabe, M.,*Ito, R., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Shoji, T.,*Yanagawa, N., Baba, T.: A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system. Jpn J Clin Oncol.: Jan 20: hyad192(2024)
*Sakai, H.,*Itani, Y., Nagasawa, T.,*Yoshida, Y., et al.: Protocol for a Prospective Cohort Study to Evaluate Changes in Sexuality in Patients With Primary Cervical Cancer Using Patient-Reported Outcomes (JGOG9004, SARAH Study), and Our Approaches to Solving the Unmet Needs of Patients With Gynecological Cancer. J Clin Gynecol Obstet.: 12(2): 59-64(2023)
*Komatsu, H.,*Matsumoto, K., Nagasawa, T., *Sato, T., et al.: A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study. Cancer Medicine.: 13:e6968(2024)
Sato, S.,*Gillette, M.,*Santiago, P,.*Kuhn, Eric., *Burgess, M.,*Doucette, Kristen.,*Feng, Yi., *Dorantes, C.,*Ippoliti, Paul.,*Hobday, S.,* Mitchell, M.,*Doberstein, K.,*Gysler, S.,*Hirsch, M.,*Schwartz, L.,*Birrer, M.,*Skates, S.,*Burns, K.,*Carr, S.,*Drapkin, R.: LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Sci Rep.: 13(1):1537(2023)
*Yagishita, S.,*Nishikawa, T.,*Yoshida, H.,* Shintani, D., Sato, S.,*Miwa, M.,*Suzuki, M.,* Yasuda, M.,*Ogitani, Y.,*Jikoh, T.,*Yonemori, K.,*Hasegawa, K.,*Hamada, A.: Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy. Clin Cancer Res.: 13;29(12): 2239-2249(2023)
英文総説
*Murakami, I.,*Machida, H.,*Morisada, T.,*Terao, Y.,*Tabata, T.,*Mikami, M.,*irashima, Y.,*Kobayashi, Y., Baba, T.,*Nagase, S.: Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review. J Gynecol Oncol.: 34(4): e49(2023)
*Shigeta, S.,*Konno, Y.,*Terai, Y.,*Morisada, T.,*Tokunaga, H., Baba, T.,*Kobayashi, Y.,*Nagase, S.: A qualitative systematic review of the significance of adjuvant therapy in patients with low-risk endometrial cancer presenting positive peritoneal cytology: a relevant study to the guideline update for endometrial cancer by the Japan society of gynecologic oncology guideline committee. Jpn J Clin Oncol. : 54(2): 217-220(2024)
*Seino, M.,*Nagase, S.,*Tokunaga, H.,*Yamagami, W., *Kobayashi, Y.,*Tabata, T.,*Kaneuchi, M.,*Hirashima, Y., *Niikura, H.,*Yoshino, K.,*Takehara, K., Baba, T., *Katabuchi, H.,*Mikami, M.: Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment. J Gynecol Oncol.: 35(1):e15(2023)
英文症例報告
*Kikuchi, K., Oyama, R., Sato, T.,*Otsuka, H., Hosomi, S., *Terata, M., Kawamura, H., Haba, G., Isurugi, C., Baba, T.: Quantitative Image Analysis for Detecting into the Myometrium of the Placenta Accreta Spectrum: A Case Report. Gynecol Obstet Open Acc.: 7: 156(2023)
Oyama, R.,*Ikebe, Tetsuro.: Internal Medicine for Dental Treatments.Patients with Medical Diseases. 1st ed. 2023 edition. Pregnancy and Breastfeeding. P 337-349. Springer Nature Singapore.
*Ishida, M., Sato, S.,*Sato, I.,*Yoshioka, A.,*Uchida, N., *Mizunuma, N.,*Hasegawa, K.,*Onishi, H.: What can cause cancer patients to attempt suicide? Thiamine deficiency mimicking the symptoms of major depressive disorder. Palliat Support Care.: 22(1): 205-208(2024)
Kagabu, M.: Evolution of Cervical Cancer Treatment with Immune Checkpoint Inhibitors in Japan. Asia Pacific Forum for Immunotherapy in Cervical Cancer. 2023. Chaina.
一般講演
Baba, T.: Safe laparoscopic hysterectomy. VAGO Pre Congress workshop with AOFOG MIGS committee Workshop: For sustainable minimally invasive surgeries from Basic to Advanced. Jun.2023. Hanoi.
Baba, T.: Fertility sparing MIS for gynaecological malignancies. VAGO Pre Congress workshop with AOFOG MIGS committee Workshop: For sustainable minimally invasive surgeries from Basic to Advanced. Jun.2023. Hanoi.
Baba, T.: What is Expected for Minimally Access Surgery (MAS) for Gynecological malignancy after SHAPE? Overseas Expert Discussion. 6th Summit Forum of the union of gynecology and obstetrics of Xinhua Hospital. Jun.2023.Shanghai/web.
Baba, T.: Lap vs Robot: which is better? Gyn Symposium 1, 12th Singapore International Congress of O&G 2023 (SICOG2023). Agu.2023. Singapore.
Baba, T.: Hysteroscopic treatment for reproductive health, infertility. Gyn Symposium 4. 12th Singapore International Congress of O&G 2023 (SICOG2023). Aug.2023. Singapore.
Baba, T.: Critical knowledge for surgeons about Myoma, atypical Myoma, and Sarcoma. Fibroids and Morcellation-Evidence, Surgical Principles, and Hands-On Simulation. FIGO2023. Oct.2023. Paris.
Baba, T.: Changing Roles of MIGS in Gynecologic Oncology. 109th Annual Congress of KSOG & 28th Seoul International Symposium. Nov.2023. Seoul.
Baba, T.: What is Expected for Minimally Access Surgery (MAS) for Gynecological malignancy after SHAPE? 2023大湾区婦人科低侵襲Summit/Forum中日婦人科新幹線深圳駅. Nov.2023. Shinsen.
Baba, T.: Cervical cancer guideline: Early stage. ASGO Guideline for Cervical Cancer. The ASGO 2023 8th Biennial Meeting.Dec. 2023.Taipei.
Baba, T.: Management of cervical cancer <2 cm and >4 cm. AOFOG Gynaecological Oncology Surgical Virtual Workshop.Mar. 2024. web
Baba, T.: Minimally invasive surgery for ovarian cancer. The 4th ICGS workshop: Integrating Review in epithelial ovarian cancer (EOC). From the beginning to the end. Mar.2024. Bangkok.
Baba, T.: Comprehensive review of chemo (drug)-therapy in EOC. The 4th ICGS workshop: Integrating Review in epithelial ovarian cancer (EOC): From the beginning to the end. Mar.2024.Bangkok.
Baba, T.: Conventional lymph Node dissection. The 4th ICGS workshop: Advances in Gynecologic Oncology Surgical Techniques: A Hands-on Cadaveric Training.Mar. 2024.Bangkok.
Baba, T.: Anatomical Considerations for GYN Cancer Surgery. The 4th ICGS workshop: Advances in Gynecologic Oncology Surgical Techniques: A Hands-on Cadaveric Training. Mar.2024.Bangkok.
Oyama, R., *Sato, Takanori., Terata, M., Kawamura, H., Haba, G., Baba, Tsukasa.: Trial of quantitative image analysis of blood flow at placental attachment site. Department of Obstetrics and Gynecology, Iwate Medical University, Japan . ISUOG World Congress.Oct.2023. Seoul.
Nagasawa, T., Shoji, T., Hosomi, S.,*Chiba, Y., Sato, S., Takatori, E., Kaido, Y., Kagabu, M., Baba, T., *Yokoyama, Y.: A phase II study of oxaliplatin with oral S-1 for patients with recurrent non-squamous cell carcinoma of uterine cervix (Tohoku Gynecologic Cancer Unit 206 study). 2023. International Gynecologic Cancer Society 2023b Annual Global Meeting.Nov.2023.Seoul.
Kagabu, M.,*Kawamura, H., Kawamura, H., Murakami, K., *Sasaki, Y., Yoshino, N., Muraki, M., Baba, T.: Efficacy of combination chemotherapy and third-generation oncolytic herpes virus therapy for cervical cancer. Annual Meeting of International Gynecologic Cancer Society .Nov.2023 . Soul.
*Tanaka, T.,*Usami, T.,*Ishikawa, M.,*Kondo, E., Kagabu, M.,*Hirabayashi, K.,*Matsumura, N.,*Sato, S.,*Nishimura, M.,*Arakawa, A., Nakamura, K.,*Konno, Y.,*Takehara, K., *Fujiwara, S.,*Sueoka, K.,*Nakamura, H.,*Koh, I., *Ito, K., *Hongo, A.: Retrospective re-evaluation of platinum-free interval and chemotherapeutic effect against subsequent platinum-containing chemotherapy in recurrent ovarian cancer patients initially treated by chemotherapy with bevacizumab. Annual Meeting of International Gynecologic Cancer Society.Nov.2023.Soul.
Chiba, Y., Kagabu, M., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Shoji, T., Baba, T.: Relative Dose Intensity of Lenvatinib for Uterine Cancer Does Not Affect the Efficacy of Combination Therapy.The 8th Biennial Meeting of Asian Society of Gynecologic Oncology. Dec.2023.Taiwan.
お問い合わせ